Non-adherence to cardiovascular medications

Kumaran Kolandaivelu1, Benjamin B Leiden2, Patrick T O'Gara3

  • 1Institute for Medical Engineering and Sciences, Massachusetts Institute of Technology, 77 Massachusetts Ave. Bldg. E25-201, Cambridge, MA 02139, USA Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA.

European Heart Journal
|October 1, 2014
PubMed

Insights

Patient non-adherence to coronary heart disease (CHD) treatments complicates care and increases risks. Developing better tools to identify patients at risk for non-adherence is crucial for improving outcomes and reducing healthcare costs.

Area of Science:

  • Cardiology
  • Patient Adherence Research
  • Health Services Research

Background:

  • Coronary heart disease (CHD) is a major global cause of death, despite existing treatments.
  • Patient non-adherence to prescribed therapies is a significant challenge in managing CHD.
  • Non-adherence can lead to incorrect treatment adjustments, increased costs, and potential patient harm.

Purpose of the Study:

  • To highlight the critical issue of patient non-adherence in coronary heart disease (CHD) management.
  • To emphasize the need for improved methods to identify patients at risk of non-adherence.
  • To underscore the importance of addressing non-adherence for better patient outcomes and cost-effectiveness.

Main Methods:

  • This abstract discusses the implications of non-adherence based on existing evidence.
  • It highlights the complexity and difficulty in defining and detecting non-adherence.
  • The need for novel screening tools is emphasized.

Main Results:

  • Non-adherence acts as a confounder in evidence-based practice.
  • It increases the risk of adverse cardiac events and mortality.
  • Current provider ability to detect non-adherence is limited.

Conclusions:

  • Addressing non-adherence in the growing CHD population is a high priority.
  • Effective identification of at-risk patients is essential for targeted interventions.
  • Improving adherence has potential clinical and economic benefits.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
746
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.4K